and 10,000 people are diagnosed with prostate cancer each year.
When diagnosed, about half of patients will experience metastatic disease, a form of the disease that affects organs and organs in the environment and has few effective treatments.
Treatment eligibility considerations for AURA cancer include those patients who are cancer-free initially and develop recurrent cancers.
“AURA is a breakthrough cancer treatment that provides both new and improved benefits to families and patients affected by recurrent bladder cancer,” said Scott Mieloski, Clinical Director of the Division of Cancer Medicine at Dana-Farber/Boston Children’s Cancer and Blood Diseases Institute and lead researcher for the pioneers trial.
All patients were followed for 6 months.
Mieloski is the driving force behind the study, as he controls the clinical flow and external support of the research team,” said Panagis Galiatsatos, MD, director of the CRC Program in Prostate Cancer, Cancer and Urologic Oncology at Dana-Farber/Boston Children’s.